Literature DB >> 20431349

Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.

Agnieszka K Witkiewicz1, Abhijit Dasgupta, Sara Sammons, Ozlem Er, Magdalena B Potoczek, Fran Guiles, Federica Sotgia, Jonathan R Brody, Edith P Mitchell, Michael P Lisanti.   

Abstract

Here, we investigated the possible predictive value of stromal caveolin-1 (Cav-1) as a candidate biomarker for clinical outcome in triple negative (TN) breast cancer patients. A cohort of 85 TN breast cancer patients was available, with the necessary annotation and nearly 12 years of follow-up data. Our primary outcome of interest in this study was overall survival. Interestingly, TN patients with high-levels of stromal Cav-1 had a good clinical outcome, with >50% of the patients remaining alive during the follow-up period. In contrast, the median survival for TN patients with moderate stromal Cav-1 staining was 33.5 months. Similarly, the median survival for TN patients with absent stromal Cav-1 staining was 25.7 months. A comparison of 5-year survival rates yields a similar pattern. TN patients with high stromal Cav-1 had a good 5-year survival rate, with 75.5% of the patients remaining alive. In contrast, TN patients with moderate or absent stromal Cav-1 levels had progressively worse 5-year survival rates, with 40 and 9.4% of the patients remaining alive. In contrast, in a parallel analysis, the levels of tumor epithelial Cav-1 had no prognostic significance. As such, the prognostic value of Cav-1 immunostaining in TN breast cancer patients is compartment-specific, and selective for an absence of Cav-1 staining in the stromal fibroblast compartment. A recursive-partitioning algorithm was used to assess which factors are most predictive of overall survival in TN breast cancer patients. In this analysis, we included tumor size, histologic grade, whether the patient received surgery, radiotherapy or chemotherapy, CK5/6, EGFR, p53 and Ki67 status, as well as the stromal Cav-1 score. This analysis indicated that stromal loss of Cav-1 expression was the most important prognostic factor for overall survival in TN breast cancer. Virtually identical results were obtained with CK5/6 (+) and/or EGFR (+) TN breast cancer cases, demonstrating that a loss of stromal Cav-1 is also a strong prognostic factor for basal-like breast cancers. Our current findings may have important implications for the close monitoring and treatment stratification of TN and basal-like breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431349      PMCID: PMC3040896          DOI: 10.4161/cbt.10.2.11983

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  22 in total

Review 1.  The myothelia (myoepithelial cells). Normal state; regressive changes; hyperplasia; tumors.

Authors:  H Hamperl
Journal:  Curr Top Pathol       Date:  1970

2.  Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.

Authors:  Emad A Rakha; Dalia Abd El-Rehim; Claire Paish; Andrew R Green; Andrew H S Lee; John F Robertson; Roger W Blamey; Douglas Macmillan; Ian O Ellis
Journal:  Eur J Cancer       Date:  2006-10-19       Impact factor: 9.162

3.  Reduction of caveolin and caveolae in oncogenically transformed cells.

Authors:  A J Koleske; D Baltimore; M P Lisanti
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

4.  Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Authors:  Katrina R Bauer; Monica Brown; Rosemary D Cress; Carol A Parise; Vincent Caggiano
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.

Authors:  Gloria Bonuccelli; Diana Whitaker-Menezes; Remedios Castello-Cros; Stephanos Pavlides; Richard G Pestell; Alessandro Fatatis; Agnieszka K Witkiewicz; Matthew G Vander Heiden; Gemma Migneco; Barbara Chiavarina; Philippe G Frank; Franco Capozza; Neal Flomenberg; Ubaldo E Martinez-Outschoorn; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

7.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

8.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.

Authors:  C W Elston; I O Ellis
Journal:  Histopathology       Date:  1991-11       Impact factor: 5.087

9.  Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia.

Authors:  Terence M Williams; Hyangkyu Lee; Michelle W-C Cheung; Alex W Cohen; Babak Razani; Puneeth Iyengar; Philipp E Scherer; Richard G Pestell; Michael P Lisanti
Journal:  J Biol Chem       Date:  2004-03-25       Impact factor: 5.157

10.  Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

Authors:  Mervi Jumppanen; Sofia Gruvberger-Saal; Päivikki Kauraniemi; Minna Tanner; Pär-Ola Bendahl; Mikael Lundin; Morten Krogh; Pasi Kataja; Ake Borg; Mårten Fernö; Jorma Isola
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

View more
  79 in total

1.  Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.

Authors:  Ubaldo E Martinez-Outschoorn; Casey Trimmer; Zhao Lin; Diana Whitaker-Menezes; Barbara Chiavarina; Jie Zhou; Chengwang Wang; Stephanos Pavlides; Maria P Martinez-Cantarin; Franco Capozza; Agnieszka K Witkiewicz; Neal Flomenberg; Anthony Howell; Richard G Pestell; Jaime Caro; Michael P Lisanti; Federica Sotgia
Journal:  Cell Cycle       Date:  2010-09-09       Impact factor: 4.534

Review 2.  The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.

Authors:  Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Stephanos Pavlides; Barbara Chiavarina; Gloria Bonuccelli; Trimmer Casey; Aristotelis Tsirigos; Gemma Migneco; Agnieszka Witkiewicz; Renee Balliet; Isabelle Mercier; Chengwang Wang; Neal Flomenberg; Anthony Howell; Zhao Lin; Jaime Caro; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-11-30       Impact factor: 4.534

3.  Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers.

Authors:  Agnieszka K Witkiewicz; Diana Whitaker-Menezes; Abhijit Dasgupta; Nancy J Philp; Zhao Lin; Ricardo Gandara; Sharon Sneddon; Ubaldo E Martinez-Outschoorn; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-03-15       Impact factor: 4.534

Review 4.  Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis.

Authors:  Stephanos Pavlides; Iset Vera; Ricardo Gandara; Sharon Sneddon; Richard G Pestell; Isabelle Mercier; Ubaldo E Martinez-Outschoorn; Diana Whitaker-Menezes; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Antioxid Redox Signal       Date:  2011-11-17       Impact factor: 8.401

5.  Monocarboxylate transporter 1 inhibitors as potential anticancer agents.

Authors:  Shirisha Gurrapu; Sravan K Jonnalagadda; Mohammad A Alam; Grady L Nelson; Mary G Sneve; Lester R Drewes; Venkatram R Mereddy
Journal:  ACS Med Chem Lett       Date:  2015-03-19       Impact factor: 4.345

Review 6.  Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment.

Authors:  Ubaldo E Martinez-Outschoorn; Stephanos Pavlides; Anthony Howell; Richard G Pestell; Herbert B Tanowitz; Federica Sotgia; Michael P Lisanti
Journal:  Int J Biochem Cell Biol       Date:  2011-02-15       Impact factor: 5.085

Review 7.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

8.  Transcription factor networks in invasion-promoting breast carcinoma-associated fibroblasts.

Authors:  A Siletz; E Kniazeva; J S Jeruss; L D Shea
Journal:  Cancer Microenviron       Date:  2012-10-23

9.  Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin.

Authors:  Rosa Sanchez-Alvarez; Ubaldo E Martinez-Outschoorn; Rebecca Lamb; James Hulit; Anthony Howell; Ricardo Gandara; Marina Sartini; Emanuel Rubin; Michael P Lisanti; Federica Sotgia
Journal:  Cell Cycle       Date:  2012-12-20       Impact factor: 4.534

10.  Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism: implications for breast cancer prevention.

Authors:  Rosa Sanchez-Alvarez; Ubaldo E Martinez-Outschoorn; Zhao Lin; Rebecca Lamb; James Hulit; Anthony Howell; Federica Sotgia; Emanuel Rubin; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.